首页 > 最新文献

Journal of Clinical and Experimental Hepatology最新文献

英文 中文
Conjugated Linoleic Acid-induced Hepatotoxicity Requiring Liver Transplant 共轭亚油酸诱发的肝中毒需要肝移植
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-21 DOI: 10.1016/j.jceh.2024.101408
Nathaniel L. Saffran, Aliza S. Gross, Allen T. Yu

Acute liver failure (ALF) typically presents with encephalopathy and impairment in the synthetic function of the liver. Weight loss supplements have been associated with ALF, and their use has only been increasing in the United States. We report a case of a 42-year-old woman with a history of Gilbert's syndrome who presented to the hospital with ALF secondary to weight loss supplements, who ultimately required liver transplantation. This is the first known case of conjugated linoleic acid (CLA) toxicity requiring liver transplantation in the United States.

急性肝衰竭(ALF)通常表现为脑病和肝脏合成功能受损。减肥补充剂与急性肝功能衰竭有关,而且在美国,减肥补充剂的使用也在不断增加。我们报告了一例 42 岁的女性病例,她有吉尔伯特综合征病史,因服用减肥补充剂继发 ALF 而入院,最终需要进行肝移植手术。这是美国第一例因共轭亚油酸(CLA)中毒而需要进行肝移植的病例。
{"title":"Conjugated Linoleic Acid-induced Hepatotoxicity Requiring Liver Transplant","authors":"Nathaniel L. Saffran,&nbsp;Aliza S. Gross,&nbsp;Allen T. Yu","doi":"10.1016/j.jceh.2024.101408","DOIUrl":"10.1016/j.jceh.2024.101408","url":null,"abstract":"<div><p>Acute liver failure (ALF) typically presents with encephalopathy and impairment in the synthetic function of the liver. Weight loss supplements have been associated with ALF, and their use has only been increasing in the United States. We report a case of a 42-year-old woman with a history of Gilbert's syndrome who presented to the hospital with ALF secondary to weight loss supplements, who ultimately required liver transplantation. This is the first known case of conjugated linoleic acid (CLA) toxicity requiring liver transplantation in the United States.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101408"},"PeriodicalIF":3.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of Hepatocellular Carcinoma in India – An Updated Review for 2024 印度肝细胞癌流行病学 - 2024 年最新回顾
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-21 DOI: 10.1016/j.jceh.2024.101447
Suprabhat Giri , Ankita Singh

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is a significant cause of morbidity and mortality, especially in patients with chronic liver disease. As a reflection of geographical variations in India, there is significant variation in the prevalence and etiological factors of HCC. In contrast to previous studies reporting viral hepatitis as the most common etiology, recent data indicates a changing etiological pattern of cirrhosis and HCC, with alcohol and metabolic dysfunction-associated steatotic liver disease (MASLD) emerging as the foremost cause. Thus, there was a need for an updated review of the current literature and databases for the changing epidemiology and etiological spectrum of HCC in India. The review included data primarily from the National Cancer Registry Program and the Global Burden of Diseases, Injuries, and Risk Factors Study, with the inclusion of other studies from India. The highlights of the present review are summarized in the following lines. Although the current incidence (2.15 per 100,000), prevalence (2.27 per 100,000), and mortality (2.21 per 100,000) rate of HCC in India remain lower compared to the global data, the annual rates of change in these parameters are higher in India. Among Indians, the present incidence, prevalence, and mortality related to HCC are higher in males, while the annual rate of change is higher in females. The Northeastern states have higher incidence, prevalence, and mortality related to HCC, but the Western states of Gujarat, Maharashtra, Goa, and Kerala are emerging as newer hotspots with higher annual rates of change in incidence, prevalence, and mortality. The incidence of HCC related to hepatitis B is on a downtrend, while those related to alcohol and MASLD are rising. Public health initiatives, awareness campaigns, and focused treatments are all necessary to combat these changes, particularly in areas with high incidence rates.

肝细胞癌(HCC)是原发性肝癌中最常见的一种,也是发病和死亡的重要原因,尤其是在慢性肝病患者中。由于印度的地域差异,HCC 的发病率和病因也存在显著差异。与以往研究报告病毒性肝炎是最常见的病因不同,最近的数据表明肝硬化和 HCC 的病因模式正在发生变化,酒精和代谢功能障碍相关性脂肪性肝病(MASLD)成为首要病因。因此,有必要对当前的文献和数据库进行更新,以了解印度 HCC 不断变化的流行病学和病因谱。综述主要包括国家癌症登记计划和全球疾病负担、伤害和风险因素研究的数据,也包括印度的其他研究。本综述的要点概述如下。尽管与全球数据相比,印度目前的 HCC 发病率(每 10 万人 2.15 例)、患病率(每 10 万人 2.27 例)和死亡率(每 10 万人 2.21 例)仍然较低,但印度这些参数的年变化率较高。在印度人中,与 HCC 相关的男性发病率、患病率和死亡率较高,而女性的年变化率较高。东北部各邦与 HCC 相关的发病率、流行率和死亡率较高,但西部的古吉拉特邦、马哈拉施特拉邦、果阿邦和喀拉拉邦正在成为新的热点地区,其发病率、流行率和死亡率的年变化率较高。与乙型肝炎相关的 HCC 发病率呈下降趋势,而与酒精和 MASLD 相关的 HCC 发病率则呈上升趋势。要应对这些变化,尤其是在发病率较高的地区,公共卫生倡议、宣传活动和重点治疗都是必要的。
{"title":"Epidemiology of Hepatocellular Carcinoma in India – An Updated Review for 2024","authors":"Suprabhat Giri ,&nbsp;Ankita Singh","doi":"10.1016/j.jceh.2024.101447","DOIUrl":"10.1016/j.jceh.2024.101447","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is a significant cause of morbidity and mortality, especially in patients with chronic liver disease. As a reflection of geographical variations in India, there is significant variation in the prevalence and etiological factors of HCC. In contrast to previous studies reporting viral hepatitis as the most common etiology, recent data indicates a changing etiological pattern of cirrhosis and HCC, with alcohol and metabolic dysfunction-associated steatotic liver disease (MASLD) emerging as the foremost cause. Thus, there was a need for an updated review of the current literature and databases for the changing epidemiology and etiological spectrum of HCC in India. The review included data primarily from the National Cancer Registry Program and the Global Burden of Diseases, Injuries, and Risk Factors Study, with the inclusion of other studies from India. The highlights of the present review are summarized in the following lines. Although the current incidence (2.15 per 100,000), prevalence (2.27 per 100,000), and mortality (2.21 per 100,000) rate of HCC in India remain lower compared to the global data, the annual rates of change in these parameters are higher in India. Among Indians, the present incidence, prevalence, and mortality related to HCC are higher in males, while the annual rate of change is higher in females. The Northeastern states have higher incidence, prevalence, and mortality related to HCC, but the Western states of Gujarat, Maharashtra, Goa, and Kerala are emerging as newer hotspots with higher annual rates of change in incidence, prevalence, and mortality. The incidence of HCC related to hepatitis B is on a downtrend, while those related to alcohol and MASLD are rising. Public health initiatives, awareness campaigns, and focused treatments are all necessary to combat these changes, particularly in areas with high incidence rates.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101447"},"PeriodicalIF":3.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141138753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the Diagnostic Dilemma of Evaluating Gallbladder Wall Thickening: Are We There Yet? 评估胆囊壁增厚的诊断难题:我们成功了吗?
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-19 DOI: 10.1016/j.jceh.2024.101450
Shravya Srinivas Rao, Avinash Kambadakone
{"title":"Navigating the Diagnostic Dilemma of Evaluating Gallbladder Wall Thickening: Are We There Yet?","authors":"Shravya Srinivas Rao,&nbsp;Avinash Kambadakone","doi":"10.1016/j.jceh.2024.101450","DOIUrl":"10.1016/j.jceh.2024.101450","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 4","pages":"Article 101450"},"PeriodicalIF":3.0,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141135285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Influence of Preoperative Trans Arterial Embolization (TAE) and Predictive Potential of Circulating Tumor Cells (CTCs) in Prognosis of Hepatocellular Carcinoma 探究术前经动脉栓塞(TAE)和循环肿瘤细胞(CTC)对肝细胞癌预后的影响
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-18 DOI: 10.1016/j.jceh.2024.101445
Shraddha Patkar , Omshree Shetty , Karishma Vyas , Vaibhavi Vengurlekar , Vishaka Kamble , Nitin Shetty , Suyash Kulkarni , Kunal Gala , Devesh Ballal , Prerak Patel , Ruchit Kansaria , Vikram Chaudhari , Mahesh Goel

Introduction

Circulating tumor cells are a promising biomarker in many malignancies. CTC dissemination during the operative procedure can lead to disease recurrence. The effect of preoperative transarterial embolization on the release of CTCs and miRNA panels and oncological outcomes in large hepatocellular carcinomas has been evaluated.

Materials and methods

The study included non-metastatic HCC >5 cm in size, that were completely resected after TAE (n = 10). Blood was collected pre-TAE, post-TAE, postoperative (day 2,30 and 180) and analyzed for the presence of CTC and miRNA (miR-885-5p, miR-22-3p, miR-642b-5p). The samples were subjected to CTC enrichment, isolation and staining using the markers CD45, EpCAM, and cytokeratin (CK). The data was analyzed using Gene Expression Suite software.

Results

The CTC enumeration resulted in three groups: Group 1- CTC present at both pre-TAE and postoperative day 30 (n = 4), Group 2- CTC present at pre-TAE and clearing at postoperative day 30 (n = 2), Group 3- No CTC detected at any stages (n = 3). Group 2 patients had better survival compared with the other groups. Downregulation of miRNA 22-3p also had favorable prognostic implications.

Conclusion

Although preoperative TAE does not seem to impact CTC shedding, CTC clearance may prove to be a valuable biomarker in prognosticating HCC. A larger study to evaluate the significance of CTCs as a prognostic marker is warranted to further evaluate these findings.

导言在许多恶性肿瘤中,循环肿瘤细胞是一种很有前景的生物标记物。CTC在手术过程中扩散会导致疾病复发。研究评估了术前经动脉栓塞对 CTCs 和 miRNA 面板的释放以及大肝细胞癌肿瘤学结果的影响。在 TAE 前、TAE 后、术后(第 2、30 和 180 天)采集血液,分析 CTC 和 miRNA(miR-885-5p、miR-22-3p、miR-642b-5p)的存在。对样本进行 CTC 富集、分离,并使用标记物 CD45、EpCAM 和细胞角蛋白(CK)进行染色。结果CTC计数结果分为三组:第 1 组--TAE 前和术后第 30 天均有 CTC(n = 4);第 2 组--TAE 前有 CTC,术后第 30 天清除(n = 2);第 3 组--任何阶段均未检测到 CTC(n = 3)。与其他组相比,第 2 组患者的生存率更高。结论虽然术前 TAE 似乎不会影响 CTC 的脱落,但 CTC 的清除可能被证明是预测 HCC 预后的重要生物标志物。为了进一步评估这些发现,有必要进行更大规模的研究,以评估 CTC 作为预后标志物的意义。
{"title":"Investigating the Influence of Preoperative Trans Arterial Embolization (TAE) and Predictive Potential of Circulating Tumor Cells (CTCs) in Prognosis of Hepatocellular Carcinoma","authors":"Shraddha Patkar ,&nbsp;Omshree Shetty ,&nbsp;Karishma Vyas ,&nbsp;Vaibhavi Vengurlekar ,&nbsp;Vishaka Kamble ,&nbsp;Nitin Shetty ,&nbsp;Suyash Kulkarni ,&nbsp;Kunal Gala ,&nbsp;Devesh Ballal ,&nbsp;Prerak Patel ,&nbsp;Ruchit Kansaria ,&nbsp;Vikram Chaudhari ,&nbsp;Mahesh Goel","doi":"10.1016/j.jceh.2024.101445","DOIUrl":"10.1016/j.jceh.2024.101445","url":null,"abstract":"<div><h3>Introduction</h3><p>Circulating tumor cells are a promising biomarker in many malignancies. CTC dissemination during the operative procedure can lead to disease recurrence. The effect of preoperative transarterial embolization on the release of CTCs and miRNA panels and oncological outcomes in large hepatocellular carcinomas has been evaluated.</p></div><div><h3>Materials and methods</h3><p>The study included non-metastatic HCC &gt;5 cm in size, that were completely resected after TAE (n = 10). Blood was collected pre-TAE, post-TAE, postoperative (day 2,30 and 180) and analyzed for the presence of CTC and miRNA (miR-885-5p, miR-22-3p, miR-642b-5p). The samples were subjected to CTC enrichment, isolation and staining using the markers CD45, EpCAM, and cytokeratin (CK). The data was analyzed using Gene Expression Suite software.</p></div><div><h3>Results</h3><p>The CTC enumeration resulted in three groups: Group 1- CTC present at both pre-TAE and postoperative day 30 (n = 4), Group 2- CTC present at pre-TAE and clearing at postoperative day 30 (n = 2), Group 3- No CTC detected at any stages (n = 3). Group 2 patients had better survival compared with the other groups. Downregulation of miRNA 22-3p also had favorable prognostic implications.</p></div><div><h3>Conclusion</h3><p>Although preoperative TAE does not seem to impact CTC shedding, CTC clearance may prove to be a valuable biomarker in prognosticating HCC. A larger study to evaluate the significance of CTCs as a prognostic marker is warranted to further evaluate these findings.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101445"},"PeriodicalIF":3.0,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141141033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining Surgical Difficulty During Open Right Lobe Donor Hepatectomy and its Prediction Using Preoperative Donor Computed Tomography Morphometry 确定开放式右叶供体肝切除术中的手术难度并利用术前供体 CT 形态测量进行预测
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-16 DOI: 10.1016/j.jceh.2024.101446
Rajnikanth Patcha , Neelendra Y. Muppala , Selvakumar Malleeswaran , Prasanna V. Gopal , Vellaichamy Katheresan , Satish Kumar , Ellango Appusamy , Joy Varghese , Sripriya Srinivas , Mettu S. Reddy

Background

There is no accepted way to define difficult donor hepatectomy (DiffDH) during open right live donor hepatectomy (ORLDH). There are also no studies exploring association between DiffDH and early donor outcomes or reliable pre-operative predictors of DiffDH.

Methods

Consecutive ORLDH performed over 18 months at a single center were included. Intraoperative parameters were used to develop an objective definition of DiffDH. The impact of DiffDH on early postoperative outcomes and achievement of textbook outcome (TO) was evaluated. Donor morphometry data on axial and coronal sections of donor computed tomography (CT) at the level of portal bifurcation were collected. Donor and graft factors predictive of DiffDH were evaluated using univariate and multivariate logistic regression.

Results

One-hundred-eleven donors (male: 40.5%, age: 34 ± 9.5 years) underwent ORLDH during the study period. The difficulty score was constructed using five intraoperative parameters, i.e., operating time, transection time, estimated blood loss, need for intraoperative vasopressors, and need for Pringle maneuver. Donors were classified as DiffDH (score ≥ 2) or standard donor hepatectomy (StDH) (score <2). Twenty-nine donors (26%) were classified as DiffDH. DiffDH donors suffered greater all-cause morbidity (P = 0.004) but not major morbidity (Clavien–Dindo score >2; P = 0.651), more perioperative transfusion (P = 0.013), increased postoperative systemic inflammatory response syndrome (P = 0.034), delay in achieving full oral diet (P = 0.047), and a 70% reduced chance of achieving TO as compared to StDH (P = 0.007). On logistic regression analysis, increasing right lobe anteroposterior depth (RLdepth) was identified as an independent predictor of DiffDH (Odds ratio: 2.0 (95% confidence interval = 1.2, 3.3), P < 0.006). Receiver operating characteristic curve analysis identified an RLdepth of >14 cm as the best predictor of DiffDH (sensitivity:79%, specificity: 66%, area under curve = 0.803, P < 0.001).

Conclusion

We report a novel definition of DiffDH and show that it is associated with worse postoperative outcomes, including a lesser chance of achieving TO. We also report that DiffDH can be predicted from readily available donor CT parameters.

背景目前还没有公认的方法来定义开放式右活体供体肝切除术(ORLDH)中的困难供体肝切除术(DiffDH)。也没有研究探讨 DiffDH 与早期供体预后之间的关系或 DiffDH 的可靠术前预测因素。采用术中参数对 DiffDH 进行客观定义。评估了DiffDH对术后早期结果和达到教科书结果(TO)的影响。收集了门静脉分叉处供体计算机断层扫描(CT)轴向和冠状切面的供体形态数据。使用单变量和多变量逻辑回归评估了可预测 DiffDH 的供体和移植物因素。结果 在研究期间,有 117 名供体(男性:40.5%,年龄:34 ± 9.5 岁)接受了 ORLDH。手术难度评分由五个术中参数构成,即手术时间、横断时间、估计失血量、术中血管加压需要量和普林格尔操作需要量。供体被分为 DiffDH(评分≥2)或标准供体肝切除术(StDH)(评分<2)。29 名供体(26%)被归类为 DiffDH。与 StDH 相比,DiffDH 供体的全因发病率更高(P = 0.004),但主要发病率不高(Clavien-Dindo 评分 >2; P = 0.651),围手术期输血更多(P = 0.013),术后全身炎症反应综合征增加(P = 0.034),实现完全口服饮食的时间推迟(P = 0.047),实现 TO 的机会减少 70%(P = 0.007)。在逻辑回归分析中,右叶前胸深度(RLdepth)的增加被确定为 DiffDH 的独立预测因素(比值比:2.0(95% 置信区间 = 1.2,3.3),P < 0.006)。结论我们报告了 DiffDH 的新定义,并表明它与较差的术后结果有关,包括较低的 TO 机会。我们还报告说,DiffDH 可以通过现成的供体 CT 参数进行预测。
{"title":"Defining Surgical Difficulty During Open Right Lobe Donor Hepatectomy and its Prediction Using Preoperative Donor Computed Tomography Morphometry","authors":"Rajnikanth Patcha ,&nbsp;Neelendra Y. Muppala ,&nbsp;Selvakumar Malleeswaran ,&nbsp;Prasanna V. Gopal ,&nbsp;Vellaichamy Katheresan ,&nbsp;Satish Kumar ,&nbsp;Ellango Appusamy ,&nbsp;Joy Varghese ,&nbsp;Sripriya Srinivas ,&nbsp;Mettu S. Reddy","doi":"10.1016/j.jceh.2024.101446","DOIUrl":"10.1016/j.jceh.2024.101446","url":null,"abstract":"<div><h3>Background</h3><p>There is no accepted way to define difficult donor hepatectomy (DiffDH) during open right live donor hepatectomy (ORLDH). There are also no studies exploring association between DiffDH and early donor outcomes or reliable pre-operative predictors of DiffDH.</p></div><div><h3>Methods</h3><p>Consecutive ORLDH performed over 18 months at a single center were included. Intraoperative parameters were used to develop an objective definition of DiffDH. The impact of DiffDH on early postoperative outcomes and achievement of textbook outcome (TO) was evaluated. Donor morphometry data on axial and coronal sections of donor computed tomography (CT) at the level of portal bifurcation were collected. Donor and graft factors predictive of DiffDH were evaluated using univariate and multivariate logistic regression.</p></div><div><h3>Results</h3><p>One-hundred-eleven donors (male: 40.5%, age: 34 ± 9.5 years) underwent ORLDH during the study period. The difficulty score was constructed using five intraoperative parameters, i.e., operating time, transection time, estimated blood loss, need for intraoperative vasopressors, and need for Pringle maneuver. Donors were classified as DiffDH (score ≥ 2) or standard donor hepatectomy (StDH) (score &lt;2). Twenty-nine donors (26%) were classified as DiffDH. DiffDH donors suffered greater all-cause morbidity (<em>P</em> = 0.004) but not major morbidity (Clavien–Dindo score &gt;2; <em>P</em> = 0.651), more perioperative transfusion (<em>P</em> = 0.013), increased postoperative systemic inflammatory response syndrome (<em>P</em> = 0.034), delay in achieving full oral diet (<em>P</em> = 0.047), and a 70% reduced chance of achieving TO as compared to StDH (<em>P</em> = 0.007). On logistic regression analysis, increasing right lobe anteroposterior depth (RLdepth) was identified as an independent predictor of DiffDH (Odds ratio: 2.0 (95% confidence interval = 1.2, 3.3), <em>P</em> &lt; 0.006). Receiver operating characteristic curve analysis identified an RLdepth of &gt;14 cm as the best predictor of DiffDH (sensitivity:79%, specificity: 66%, area under curve = 0.803, <em>P</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>We report a novel definition of DiffDH and show that it is associated with worse postoperative outcomes, including a lesser chance of achieving TO. We also report that DiffDH can be predicted from readily available donor CT parameters.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101446"},"PeriodicalIF":3.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141055744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH 治疗非酒精性脂肪肝和非酒精性脂肪性肝炎的新组合--沙格列扎和维生素 E
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-14 DOI: 10.1016/j.jceh.2024.101449
Federica Tavaglione, Rohit Loomba
{"title":"Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH","authors":"Federica Tavaglione,&nbsp;Rohit Loomba","doi":"10.1016/j.jceh.2024.101449","DOIUrl":"10.1016/j.jceh.2024.101449","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 5","pages":"Article 101449"},"PeriodicalIF":3.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141023596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First Report of Two-stage Living Donor Liver Transplantation to Avoid Futility and Ensure Double Equipoise in Acute Liver Failure Complicated by Toxic Liver Syndrome 首次报告两阶段活体肝移植,以避免急性肝功能衰竭并发中毒性肝脏综合征的无用性并确保双平衡
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-09 DOI: 10.1016/j.jceh.2024.101443
Amarnath Kadimella , Chandan K. Kedarisetty , Ravi Raya , Rajgopal M. Acharya , Smith Kadakia , Ganesh Chowhan , Gottimukkala Jayalaxmi , Mettu S. Reddy

Acute hepatic failure may occasionally be complicated by toxic liver syndrome. Emergency hepatectomy for stabilization followed by delayed graft implantation is a recognized strategy in such cases in the setting of deceased donor liver transplantation. Living donor liver transplantation adds additional complexity to this scenario as the donor liver is a directed donation and failure to stabilize the patient after emergency hepatectomy can lead to a futile live donor hepatectomy, hepar-divisum, or an orphan graft. We report a case where the two-stage strategy was utilized to circumvent this situation. A patient with toxic liver syndrome underwent emergency hepatectomy and was closely monitored in the operating theater. A live donor hepatectomy was started after the recipient demonstrated cardiovascular and neurological stabilization. Graft implantation was completed after an anhepatic period of 9.45 h. To our knowledge, this is the first reported instance of using the two-stage strategy in living-donor-liver-transplantation for toxic liver syndrome to prevent futile donor surgery and achieve double equipoise.

急性肝功能衰竭偶尔会并发中毒性肝脏综合征。紧急肝切除以稳定病情,然后延迟移植肝的植入,是在已故供体肝移植情况下处理此类病例的公认策略。活体肝移植增加了这种情况的复杂性,因为捐献的肝脏是定向捐献的,紧急肝切除术后如果不能稳定患者病情,可能会导致无用的活体肝切除术、肝二分裂或无主移植物。我们报告了一个利用两阶段策略避免这种情况的病例。一名患有中毒性肝脏综合征的患者接受了紧急肝切除术,并在手术室接受了严密监测。在受体的心血管和神经功能稳定后,开始进行活体肝切除术。据我们所知,这是首次报道在中毒性肝综合征的活体肝移植中使用两阶段策略,以防止供体手术徒劳无功并实现双平衡。
{"title":"First Report of Two-stage Living Donor Liver Transplantation to Avoid Futility and Ensure Double Equipoise in Acute Liver Failure Complicated by Toxic Liver Syndrome","authors":"Amarnath Kadimella ,&nbsp;Chandan K. Kedarisetty ,&nbsp;Ravi Raya ,&nbsp;Rajgopal M. Acharya ,&nbsp;Smith Kadakia ,&nbsp;Ganesh Chowhan ,&nbsp;Gottimukkala Jayalaxmi ,&nbsp;Mettu S. Reddy","doi":"10.1016/j.jceh.2024.101443","DOIUrl":"10.1016/j.jceh.2024.101443","url":null,"abstract":"<div><p>Acute hepatic failure may occasionally be complicated by toxic liver syndrome. Emergency hepatectomy for stabilization followed by delayed graft implantation is a recognized strategy in such cases in the setting of deceased donor liver transplantation. Living donor liver transplantation adds additional complexity to this scenario as the donor liver is a directed donation and failure to stabilize the patient after emergency hepatectomy can lead to a futile live donor hepatectomy, hepar-divisum, or an orphan graft. We report a case where the two-stage strategy was utilized to circumvent this situation. A patient with toxic liver syndrome underwent emergency hepatectomy and was closely monitored in the operating theater. A live donor hepatectomy was started after the recipient demonstrated cardiovascular and neurological stabilization. Graft implantation was completed after an anhepatic period of 9.45 h. To our knowledge, this is the first reported instance of using the two-stage strategy in living-donor-liver-transplantation for toxic liver syndrome to prevent futile donor surgery and achieve double equipoise.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101443"},"PeriodicalIF":3.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience of Performing Hepatic Interventional Radiological Procedures in a Tertiary Care Hospital in Odisha: A Case Series 在奥迪沙邦一家三级医院开展肝脏介入放射手术的经验,病例系列
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-08 DOI: 10.1016/j.jceh.2024.101436
Dibya Lochan Praharaj , Swati Das , Vedavyas Mohapatra , Bipadabhanjan Mallick , Preetam Nath , Sarat Chandra Panigrahi , Suprabhat Giri , Saroj Kanta Sahu , Anil Chandra Anand , Subrat Kumar Acharya

Introduction

During last few decades, radiological interventions have played crucial role in the management of the patients with chronic liver diseases. Various procedures including transjugualar intrahepatic portosystemic shunt (TIPS), transjugular liver biopsy (TJLB), transarterial chemoembilization (TACE)/transarterial radioembolization (TARE), balloon retrograde transvenous obliteration (BRTO) and plug-assisted retrograde transvenous obliteration (PARTO) are being performed safely and have significantly improved clinical outcomes in these patients. The technical and clinical success depend on appropriate patient selection along with thorough knowledge and experience to perform these procedures. On the other hand, few adverse events may also be associated with these procedures. The intervention radiologist and hepatologists should identify and treat these complications at the earliest so as to improve outcome of the patient.

Materials and methods

About 25 hepatic intervention radiology procedures were performed in our center from January 2022 to 2023 May. Among these we have selected five patients who underwent TACE/TIPS/DIPS in our institute. We have selected these cases as in each of these cases we encountered some interesting outcomes/complications which were managed successfully.

Results

The first case describes 33-year-old male with POEM syndrome and Budd Chiari Syndrome (BCS) who underwent TIPS and immediately had blockade of the stent. The second case is of a 43 years old male having BCS, refractory ascites with umbilical and inguinal hernia. The third case is of a 40 years old female with decompensated cirrhosis who underwent TIPS for portal hypertensive gastropathy. The fourth case is of a 51-years’ female with decompensated cirrhosis with sarcopenia. Finally, the fifth case describes 24-year-old female with BCS and hepatocellular carcinoma. In this article we discuss the procedure and clinical course of the patients following the procedure.

Conclusion

Hepatic radiological interventions though widely used can be associated with unusual albeit life threatening complications. Appropriate patient selection and thorough knowledge of procedure along with early diagnosis and management of these complications are key to obtain satisfying long term outcomes.

导言在过去几十年中,放射介入在慢性肝病患者的治疗中发挥了至关重要的作用。包括经颈静脉肝内门体分流术(TIPS)、经颈静脉肝活检术(TJLB)、经动脉化疗栓塞术(TACE)/经动脉放射栓塞术(TARE)、球囊逆行经静脉阻塞术(BRTO)和塞子辅助逆行经静脉阻塞术(PARTO)在内的各种手术正在安全进行,并显著改善了这些患者的临床疗效。技术和临床成功与否取决于对患者的适当选择以及实施这些手术的全面知识和经验。另一方面,这些手术也可能会出现一些不良事件。材料和方法2022 年 1 月至 2023 年 5 月,本中心共进行了约 25 例肝放射介入手术。其中,我们选择了五例在本院接受 TACE/TIPS/DIPS 的患者。第一例患者 33 岁,男性,患有 POEM 综合征和 Budd Chiari 综合征(BCS),接受 TIPS 后立即出现支架阻塞。第二个病例是一名 43 岁的男性,患有 BCS、难治性腹水和脐疝及腹股沟疝。第三例是一名 40 岁的女性,患有失代偿期肝硬化,因门脉高压性胃病接受了 TIPS 手术。第四个病例是一名 51 岁的女性失代偿期肝硬化患者,患有肌肉疏松症。最后,第五个病例是一名患有 BCS 和肝细胞癌的 24 岁女性。本文讨论了手术过程和术后患者的临床病程。 结论肝脏放射介入虽然应用广泛,但也可能会出现不寻常的并发症,尽管这些并发症可能危及生命。适当选择患者、全面了解手术方法以及早期诊断和处理这些并发症是获得令人满意的长期疗效的关键。
{"title":"Experience of Performing Hepatic Interventional Radiological Procedures in a Tertiary Care Hospital in Odisha: A Case Series","authors":"Dibya Lochan Praharaj ,&nbsp;Swati Das ,&nbsp;Vedavyas Mohapatra ,&nbsp;Bipadabhanjan Mallick ,&nbsp;Preetam Nath ,&nbsp;Sarat Chandra Panigrahi ,&nbsp;Suprabhat Giri ,&nbsp;Saroj Kanta Sahu ,&nbsp;Anil Chandra Anand ,&nbsp;Subrat Kumar Acharya","doi":"10.1016/j.jceh.2024.101436","DOIUrl":"10.1016/j.jceh.2024.101436","url":null,"abstract":"<div><h3>Introduction</h3><p>During last few decades, radiological interventions have played crucial role in the management of the patients with chronic liver diseases. Various procedures including transjugualar intrahepatic portosystemic shunt (TIPS), transjugular liver biopsy (TJLB), transarterial chemoembilization (TACE)/transarterial radioembolization (TARE), balloon retrograde transvenous obliteration (BRTO) and plug-assisted retrograde transvenous obliteration (PARTO) are being performed safely and have significantly improved clinical outcomes in these patients. The technical and clinical success depend on appropriate patient selection along with thorough knowledge and experience to perform these procedures. On the other hand, few adverse events may also be associated with these procedures. The intervention radiologist and hepatologists should identify and treat these complications at the earliest so as to improve outcome of the patient.</p></div><div><h3>Materials and methods</h3><p>About 25 hepatic intervention radiology procedures were performed in our center from January 2022 to 2023 May. Among these we have selected five patients who underwent TACE/TIPS/DIPS in our institute. We have selected these cases as in each of these cases we encountered some interesting outcomes/complications which were managed successfully.</p></div><div><h3>Results</h3><p>The first case describes 33-year-old male with POEM syndrome and Budd Chiari Syndrome (BCS) who underwent TIPS and immediately had blockade of the stent. The second case is of a 43 years old male having BCS, refractory ascites with umbilical and inguinal hernia. The third case is of a 40 years old female with decompensated cirrhosis who underwent TIPS for portal hypertensive gastropathy. The fourth case is of a 51-years’ female with decompensated cirrhosis with sarcopenia. Finally, the fifth case describes 24-year-old female with BCS and hepatocellular carcinoma. In this article we discuss the procedure and clinical course of the patients following the procedure.</p></div><div><h3>Conclusion</h3><p>Hepatic radiological interventions though widely used can be associated with unusual albeit life threatening complications. Appropriate patient selection and thorough knowledge of procedure along with early diagnosis and management of these complications are key to obtain satisfying long term outcomes.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101436"},"PeriodicalIF":3.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141052865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medically Tailored Meals for Patients With Cirrhosis and Hepatic Encephalopathy: The BRAINFOOD Proof-of-concept Trial 肝硬化和肝性脑病患者的药膳:BRAINFOOD 概念验证试验
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-07 DOI: 10.1016/j.jceh.2024.101439
Elliot B. Tapper , Zachary M. Saleh , Sam Nikirk , Jasmohan Bajaj , Xi Chen , Anna S-F. Lok

Background and aims

Guidelines recommend that patients with hepatic encephalopathy (HE) receive a high-protein diet (roughly 1 g/kg actual body weight). Concommitant sodium restriction, low health literacy, and food insecurity limit patients’ ability to meet this goal. We aimed to determine the feasibility of home-delivered high-protein medically tailored meals (MTMs) for patients with a recent episode of overt HE.

Methods

We enrolled patients with prior overt HE on active HE therapy in a 6-month trial of MTM. All received 21 home-delivered meals/week with protein snacks (mid-day and bedtime) for 12 weeks. Patients completed follow-up at week 24. The primary outcome was feasibility. Additional outcomes included change in protein and micronutrient intake (measured using 24 h dietary recalls performed by dieticians), cognitive function (Animal Naming Test [ANT]; EncephalApp Stroop), physical function (Liver Frailty Index [LFI]), and quality of life (Short Form-8 Health Survey [SF-8]). Healthcare utilization was also assessed.

Results

Ten patients competed the study with >90% of MTM consumed. Protein intake rose from 74.6 ± 25.1 g at baseline to 93.8 ± 24.3 g on MTM (P = 0.04). Branched-chain amino acids also increased—valine 3.73 ± 1.26 g to 5.17 ± 1.28 g, isoleucine 3.32 ± 1.18 to 4.69 ± 1.55, leucine 5.83 ± 2.00 to 7.49 ± 2.07, all P < 0.001. The LFI score improved from 4.42 ± 0.32 to 3.96 ± 0.82 by the end of the MTM phase (P = 0.03). SF-8 quality-of-life scores improved from 55.5 ± 15.5 at baseline to 64.7 ± 18.3 after the MTM phase, to 64.4 ± 19.1 at the end of the study (P = 0.1). EncephalApp Stroop time improved from 227 ± 94 to 194 ± 58s by the end of the MTM phase (P = 0.08). ANT scores were similarly non-significantly improved.

Conclusion

Home-delivered MTMs are feasible, increase protein consumption, and may improve patient wellbeing. A randomized trial is needed.

背景和目的指南建议肝性脑病(HE)患者接受高蛋白饮食(大约每公斤实际体重 1 克)。同时存在的钠限制、健康知识水平低和食物不安全限制了患者实现这一目标的能力。我们的目的是确定为近期发作过明显高血压的患者提供高蛋白家庭定制餐(MTM)的可行性。方法我们招募了接受过明显高血压积极治疗的患者参加为期 6 个月的 MTM 试验。在为期 12 周的试验中,所有患者每周接受 21 次送餐上门服务,并提供蛋白质点心(中午和睡前)。患者在第 24 周完成随访。主要结果是可行性。其他结果包括蛋白质和微量营养素摄入量的变化(通过营养师进行的 24 小时饮食回顾测量)、认知功能(动物命名测试 [ANT];EncephalApp Stroop)、身体功能(肝脏虚弱指数 [LFI])和生活质量(简表-8 健康调查 [SF-8])。此外,还对医疗保健的使用情况进行了评估。蛋白质摄入量从基线时的 74.6 ± 25.1 克增加到 MTM 后的 93.8 ± 24.3 克(P = 0.04)。支链氨基酸也有所增加--缬氨酸从 3.73 ± 1.26 g 增加到 5.17 ± 1.28 g,异亮氨酸从 3.32 ± 1.18 增加到 4.69 ± 1.55,亮氨酸从 5.83 ± 2.00 增加到 7.49 ± 2.07,所有 P 均为 0.001。在 MTM 阶段结束时,LFI 分数从 4.42 ± 0.32 降至 3.96 ± 0.82(P = 0.03)。SF-8 生活质量评分从基线时的 55.5 ± 15.5 分提高到 MTM 阶段后的 64.7 ± 18.3 分,再提高到研究结束时的 64.4 ± 19.1 分(P = 0.1)。到 MTM 阶段结束时,脑应用 Stroop 时间从 227±94 秒缩短至 194±58 秒(P = 0.08)。结论居家 MTM 是可行的,它能增加蛋白质的摄入量,并能改善患者的健康状况。需要进行随机试验。
{"title":"Medically Tailored Meals for Patients With Cirrhosis and Hepatic Encephalopathy: The BRAINFOOD Proof-of-concept Trial","authors":"Elliot B. Tapper ,&nbsp;Zachary M. Saleh ,&nbsp;Sam Nikirk ,&nbsp;Jasmohan Bajaj ,&nbsp;Xi Chen ,&nbsp;Anna S-F. Lok","doi":"10.1016/j.jceh.2024.101439","DOIUrl":"10.1016/j.jceh.2024.101439","url":null,"abstract":"<div><h3>Background and aims</h3><p>Guidelines recommend that patients with hepatic encephalopathy (HE) receive a high-protein diet (roughly 1 g/kg actual body weight). Concommitant sodium restriction, low health literacy, and food insecurity limit patients’ ability to meet this goal. We aimed to determine the feasibility of home-delivered high-protein medically tailored meals (MTMs) for patients with a recent episode of overt HE.</p></div><div><h3>Methods</h3><p>We enrolled patients with prior overt HE on active HE therapy in a 6-month trial of MTM. All received 21 home-delivered meals/week with protein snacks (mid-day and bedtime) for 12 weeks. Patients completed follow-up at week 24. The primary outcome was feasibility. Additional outcomes included change in protein and micronutrient intake (measured using 24 h dietary recalls performed by dieticians), cognitive function (Animal Naming Test [ANT]; EncephalApp Stroop), physical function (Liver Frailty Index [LFI]), and quality of life (Short Form-8 Health Survey [SF-8]). Healthcare utilization was also assessed.</p></div><div><h3>Results</h3><p>Ten patients competed the study with &gt;90% of MTM consumed. Protein intake rose from 74.6 ± 25.1 g at baseline to 93.8 ± 24.3 g on MTM (<em>P</em> = 0.04). Branched-chain amino acids also increased—valine 3.73 ± 1.26 g to 5.17 ± 1.28 g, isoleucine 3.32 ± 1.18 to 4.69 ± 1.55, leucine 5.83 ± 2.00 to 7.49 ± 2.07, all <em>P</em> &lt; 0.001. The LFI score improved from 4.42 ± 0.32 to 3.96 ± 0.82 by the end of the MTM phase (<em>P</em> = 0.03). SF-8 quality-of-life scores improved from 55.5 ± 15.5 at baseline to 64.7 ± 18.3 after the MTM phase, to 64.4 ± 19.1 at the end of the study (<em>P</em> = 0.1). EncephalApp Stroop time improved from 227 ± 94 to 194 ± 58s by the end of the MTM phase (<em>P</em> = 0.08). ANT scores were similarly non-significantly improved.</p></div><div><h3>Conclusion</h3><p>Home-delivered MTMs are feasible, increase protein consumption, and may improve patient wellbeing. A randomized trial is needed.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 6","pages":"Article 101439"},"PeriodicalIF":3.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141029007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Surgical Management of Giant Mucinous Cystic Neoplasm of Liver (MCN-L) Presenting With Peritoneal Rupture and Biliary Prolapse: Case Report and Review of Literature 成功手术治疗伴有腹膜破裂和胆道脱垂的肝脏巨大粘液囊性肿瘤(MCN-L):病例报告和文献综述。
IF 3 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-05-07 DOI: 10.1016/j.jceh.2024.101441
Ruchi Rastogi , Subhash Gupta , Sanjiv Saigal , Mukesh Kumar , Rohan Luthra , Riti Agarwal , Bharat Aggarwal

Mucinous cystic neoplasms of liver (MCN-L) are generally considered benign indolent cystic liver lesions, not associated with significant clinical symptoms in majority of patients. However, rarely these benign-appearing lesions may have a complicated clinical course, presenting with jaundice, acute abdomen, or malignant transformation. We report one such rare clinical presentation of MCN-L presenting with obstructive jaundice and abdominal pain due to prolapse of cystic component in biliary system and peritoneal rupture occurring simultaneously. Despite the complex nature of presentation, it was successfully managed surgically with normal follow-up imaging.

肝脏黏液囊性瘤(MCN-L)通常被认为是良性、惰性的肝脏囊性病变,大多数患者不会出现明显的临床症状。然而,在极少数情况下,这些看似良性的病变可能会出现复杂的临床过程,表现为黄疸、急腹症或恶性转化。我们报告的 MCN-L 就是这种罕见的临床表现之一,由于胆道系统囊性成分脱垂和腹膜破裂同时发生,患者出现梗阻性黄疸和腹痛。尽管病情复杂,但手术治疗成功,随访造影正常。
{"title":"Successful Surgical Management of Giant Mucinous Cystic Neoplasm of Liver (MCN-L) Presenting With Peritoneal Rupture and Biliary Prolapse: Case Report and Review of Literature","authors":"Ruchi Rastogi ,&nbsp;Subhash Gupta ,&nbsp;Sanjiv Saigal ,&nbsp;Mukesh Kumar ,&nbsp;Rohan Luthra ,&nbsp;Riti Agarwal ,&nbsp;Bharat Aggarwal","doi":"10.1016/j.jceh.2024.101441","DOIUrl":"10.1016/j.jceh.2024.101441","url":null,"abstract":"<div><p>Mucinous cystic neoplasms of liver (MCN-L) are generally considered benign indolent cystic liver lesions, not associated with significant clinical symptoms in majority of patients. However, rarely these benign-appearing lesions may have a complicated clinical course, presenting with jaundice, acute abdomen, or malignant transformation. We report one such rare clinical presentation of MCN-L presenting with obstructive jaundice and abdominal pain due to prolapse of cystic component in biliary system and peritoneal rupture occurring simultaneously. Despite the complex nature of presentation, it was successfully managed surgically with normal follow-up imaging.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":"14 5","pages":"Article 101441"},"PeriodicalIF":3.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141054378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Experimental Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1